Assistant Managing Editor Back before Ironwood Pharmaceuticals Inc

Assistant Managing Editor Buyout speculation fueled by the late January approval of depression drug Viibryd (vilazodone) – not to mention last week's chatter after President and CEO Drew Fromkin cancelled his presentation at BIO CEO – ended Tuesday with a resounding thud, as Clinical Data Inc

BioWorld Today Assistant Managing Editor Buyout speculation fueled by the late January approval of depression drug Viibryd (vilazodone) – not to mention last week's chatter after President and CEO Drew Fromkin cancelled his presentation at BIO CEO – ended Tuesday with a resounding thud, as Clinical Data Inc

Assistant Managing Editor It would be easy to view Merck & Co

Assistant Managing Editor AVEO Pharmaceuticals Inc

These challenges clearly affect everybody in the health care business," Gautam Jaggi, EY senior manager and managing editor of the report, told BioWorld Today

Assistant Managing Editor If the three initial public offerings (IPO) to price this month – Pacira Pharmaceuticals Inc., Endocyte Inc

Assistant Managing Editor Looking to pad its immunology portfolio, Cephalon Inc

Assistant Managing Editor If the three initial public offerings to price late last week – Pacira Pharmaceuticals Inc., Endocyte Inc

Assistant Managing Editor Since it was founded in 2008, CureFAKtor Pharmaceuticals LLC remained under the radar until recent orphan designation for lead product CFAK-C4 in pancreatic cancer – not to mention some impressive preclinical data at the ASCO Gastrointestinal Cancers Symposium last month – put the firm on the map

BioWorld Today Assistant Managing Editor A day after Pacira Pharmaceuticals Inc

Assistant Managing Editor Worries that generic vancomycin could cut into the market potential for Optimer Pharmaceuticals Inc.'s Clostridium difficile infection (CDI) drug fidaxomicin have been eased somewhat, with Astellas Pharma Europe Ltd

Assistant Managing Editor The FDA's rejection of Orexigen Inc.'s Contrave (naltrexone HCl/bupropion) last week left the biotech industry 0 for 3 in the large-market obesity space

Assistant Managing Editor A day after Pacira Pharmaceuticals Inc

Assistant Managing Editor Pacira Pharmaceuticals Inc.'s $42 million initial public offering – the first biotech IPO out of the gate in 2011 – looks a lot like the pricings of 2010

Assistant Managing Editor BioMarin Pharmaceutical Inc

Assistant Managing Editor Depomed Inc

Assistant Managing Editor Shares of NPS Pharmaceuticals Inc

Assistant Managing Editor Prosensa NV was the talk of the Duchenne's muscular dystrophy (DMD) space earlier this month when partner GlaxoSmithKline plc launched a Phase III study of antisense product GSK2402968 in patients with the progressive, inherited muscle-wasting disease. (See BioWorld Today, Jan. 27, 2011.) But coming up close behind is AVI-4658, an exon-skipping drug that developer AVI BioPharma Inc